BIR
The British Institute of Radiology
1897 125 Years 2022

BIR ANNUAL RADIOTHERAPY AND ONCOLOGY MEETING 2022

31 March–1 April 2022
etc.venues St Paul's, London

#BIRTO22

14 CPD credits
(7 creditsper day)

BIR ANNUAL RADIOTHERAPY AND ONCOLOGY MEETING 2022

This is the second meeting for the BIR, which brings together speakers from around the world and national experts too, to share experiences and expertise in a wide range of aspects for today's cutting-edge radiotherapy and oncology. Planned as a blended, hybrid meeting (enabling both face-to-face and virtual attendance and presentation), the latest techniques, technologies, methods and hot-topics will be discussed in this comprehensive meeting taking place over two days. Renewed opportunities aplenty for networking with fellow professionals and discussing the latest offerings from manufacturers.

Schedule of event

Day one

09:00 Registration opens
09:20 Welcome speech
09:30 Lecture begins
17:00 Teaching session
18:00 Close of day

Day two

08:30 Teaching session
09:00 Registration opens
09:30 Lecture begins
17:30 Close of day

Who should attend?

This event will appeal to anyone working within radiotherapy and oncology including clinical oncologists, radiographers, physicists, service managers, Linac and IT engineers, dosimetrists, manufacturers and department heads.

Five reasons to attend

1. Enhance your knowledge
2. Hear expert opinion and share your own
3. Refresh your understanding
4. Share your own research
5. Network with colleagues, peers and industry representatives

BIR ANNUAL RADIOTHERAPY AND ONCOLOGY MEETING 2022

ePosters

There will be electronic posters in an online format, which can be viewed anytime from a computer, laptop or mobile device.

Headline sessions

Plenary lecture
Professor Andy Beavis
Head of Medical Physics
Hull University Teaching Hospitals NHS Foundation Trust

Professor Ranald Mackay
Director
Christie Medical Physics and Engineering
Thursday 31 March 14:00

Plenary lecture
Professor Sandra Demaria
Professor of Radiation Oncology, Pathology and Laboratory Medicine
Weil Cornell Medicine
Friday 1 April 14:00

Teaching sessions

Challenging radiotherapy planning / Radiomics
Thursday 31 March 17:00

Adaptive radiotherapy / Brachytherapy
Friday 1 April 08:30

BIR ANNUAL RADIOTHERAPY AND ONCOLOGY MEETING 2022 WELCOMES ITS INDUSTRY PARTNERS

Platinum Sponsors

Advanced Accelerator Applications, S.A. (AAA), a Novartis company, is an innovative medicines company developing targeted radioligand therapies and precision imaging radioligands for oncology. We are committed to transforming patients' lives by leading innovation in nuclear medicine. AAA currently has over 1,000 employees working across 31 sites in 12 countries (Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the US). The company also has global manufacturing capabilities with 19 facilities in eight countries, and six research & development sites. For more information, please visit: https://www.adacap.com/

Bayer's Radiology business is well placed to be the partner of choice in helping NHS trusts to address the many challenges faced today including the increasing need for governance to demonstrate best practice and improving patient care within increasing financial constraints. With market-leading contrast media and power injector systems, Bayer is able to offer innovative patient care and with the addition of its informatics platform, it can support radiology departments in driving protocol standardisation and easily accessible audit data that enable departments to meet further challenges faced around contrast and radiation dose management. 0118 2063999 www.radiology.bayer.co.uk

GE Healthcare is a leading provider of medical imaging, monitoring, and life science technologies. GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services to help providers, researchers and life sciences companies in their mission to improve outcomes for patients around the world.

Siemens Healthineers is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalising healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care to patients. For more information and latest product line visit www.siemens-healthineers.co.uk

Enabling better health and better care at lower cost Philips is a leading health technology company focused on improving people`s lives across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that improve people`s health and enable better outcomes. Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. www.philips.co.uk/healthcare

Premium sponsor

For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter, Facebook and LinkedIn.

A pioneer in precision radiation medicine, Elekta develops and supports a range of advanced linear accelerators (linacs) that enable physicians to deliver precise, rapid and patient-specific radiotherapy for individuals with cancer. Elekta's line of high definition digital accelerators includes the latest generation Versa HD™ – a system designed to treat a spectrum of tumors throughout the body using both conventional and highly sophisticated techniques – as well as the clinically-proven and widely used Elekta Synergy® and Elekta Infinity™ linacs.

Elekta Unity is a state-of-the art MR-Linac that is defining a new standard for personalized radiation therapy based on real-time high resolution anatomical and biological MRI at the point-of-care. Unity combines a Philips high-field 1.5T MRI scanner with a best-in-class 7MV linear accelerator and breakthrough online dose replanning software that are fully integrated to enable adaptive radiotherapy and real-time target monitoring.

MOSAIQ® Plaza is a comprehensive suite of digital tools that works seamlessly with Elekta radiotherapy systems to provide the foundation for intelligence-driven, value-based healthcare. MOSAIQ Plaza's smart data center connects healthcare professionals to patients through every step of their journey to ensure efficient, standardized daily practice. Bringing people and information together, MOSAIQ Plaza allows departments to continuously improve their processes, reduce costs and touch more patients' lives.

Thursday 31 March

Stream A

09:00	**Registration and refreshments**
09:20	**Welcome and introduction**

Session 1: Patient voices

09:30	**Radiotherapy trials – a patient perspective** Julie Wolfarth, The Institute of Cancer Research
10:00	**Immunotherapy perspective** Mrs Nicola Blackler, Head of Treatment Planning, Plymouth Hospital NHS Trust
10:30	**Patient volunteer improving cancer pathway** Speaker to be confirmed
11:00	**Break**

Session 2: Practice changing clinical trials

11:30	**Clinical trials in informed SBRT** Speaker to be confirmed
12:00	**Clinical trials in informed breast** Speaker to be confirmed
12:30	**Urology** Speaker to be confirmed
13:00	**Lunch** **Lunchtime symposium: Worldwide service delivery issues** Speaker to be confirmed
14:00	**Plenary session: 'Debate – X-rays or MR for on-treatment adaptive radiotherapy'** Professor Andy Beavis, Head of Medical Physics, Hull University Teaching Hospitals NHS Foundation Trust; and Professor Ranald MacKay, Director, Christie Medical Physics and Engineering
15:00	**Break**

Session 3: Optimising resources – reuse / recycle / substainability

15:30	**Title to be confirmed** Speaker to be confirmed
16:00	**Title to be confirmed** Speaker to be confirmed
16:30	**Title to be confirmed** Speaker to be confirmed

Teaching session: Challenging radiotherapy planning

17:00	Kirsty Blythe, Radiotherapy Physics, Guy's and St Thomas' NHS Foundation Trust
18:00	**Close of day**

Thursday 31 March

Stream B

09:00	**Registration and refreshments**
09:20	**Welcome and introduction**
Session 1: MR informed radiotherapy	
09:30	**Practicalities of MR sim and MR treatment delivery from a radiographers view** Trina Herbert, MR Linac Operational Superintendent, The Royal Marsden NHS Foundation Trust
10:00	**Radiotherapy beyond geometric adaption – MR as biomarker to inform biological radiotherapy adaption** Uulke van der Heide, Professor, Leiden UMC
10:30	**MR-guided radiotherapy** Dr Shaista Hafeez, Consultant Oncologist, Institute of Cancer Research
11:00	**Break**
Session 2: In practice discussions	
11:30	**Comfort study** Mr Simon Goldsworthy, Principal Research Radiographer, Somerset NHS Foundation Trust
12:00	**Motion management** Speaker to be confirmed
12:45	**Radiobiology** Speaker to be confirmed
13:00	**Lunch** **Lunchtime symposium: Worldwide service delivery issues** Speaker to be confirmed
14:00	**Plenary session: 'Debate – X-rays or MR for on-treatment adaptive radiotherapy'** Professor Andy Beavis, Head of Medical Physics, Hull University Teaching Hospitals NHS Foundation Trust; and Professor Ranald MacKay, Director, Christie Medical Physics and Engineering
15:00	**Break**
Session 3: Manufacturer session	
15:30	**Title to be confirmed** Speaker to be confirmed, Elekta
15:45	**Title to be confirmed** Speaker to be confirmed
16:00	**Title to be confirmed** Speaker to be confirmed
16:15	**Title to be confirmed** Speaker to be confirmed
16:30	**Title to be confirmed** Speaker to be confirmed
16:45	**Title to be confirmed** Speaker to be confirmed
Teaching session: Radiomics	
17:00	Speaker to be confirmed
18:00	**Close of day**

Friday 1 April

Stream A

Teaching session: Adaptive radiotherapy

08:30	Professor Uwe Oelfke, Deputy Head of the Division of Radiotherapy and Imaging, Head of the Joint Department of Physics, The Institute of Cancer Research

09:00	**Registration and refreshments**

Session 1: Adaptive radiotherapy

09:30	**Title to be confirmed** Speaker to be confirmed
10:00	**Title to be confirmed** Speaker to be confirmed
10:30	**Title to be confirmed** Speaker to be confirmed

11:00	**Break**

Session 2: Engineering / IT / Infrastructure

11:30	**The Clatterbridge Cancer Centre – 2020 onwards** Dr Carl Rowbottom, Head of Medical Physics, Clatterbridge Cancer Centre
12:00	**Title to be confirmed** Dr Simeon Nill, Clinical Scientist, The Royal Marsden Hospital and Institute of Cancer Research
12:30	**Title to be confirmed** Speaker to be confirmed

13:00	**Lunch** **Lunchtime symposium** Speaker to be confirmed

14:00	**Plenary session: 'Immuno-radiotherapy'** Professor Sandra Demaria, Professor of Radiation Oncology, Pathology and Laboratory Medicine, Weil Cornell Medicine

15:00	**Break**

Session 3: Particle and other innovative treatments

15:30	**High energy electrons** Speaker to be confirmed
16:00	**Proton therapy** Dr Antony Lomax, Chief Medical Physicist, Paul Scherrer Institut
16:30	**Title to be confirmed** Speaker to be confirmed

17:00	**Plenary session: Role extension and skill mix** Speaker to be confirmed

17:30	**Close of event**

Friday 1 April

Stream B

Teaching session: Brachytherapy – what good looks like?

08:30	Speaker to be confirmed

09:00	**Registration and refreshments**

Session 1: SRS / SABR / Oligomets

09:30	**Title to be confirmed** Speaker to be confirmed
09:45	**Title to be confirmed** Speaker to be confirmed
10:00	**Title to be confirmed** Speaker to be confirmed

11:00	**Break**

Session 2: Advances in radiotherapy treatment planning

11:30	**Title to be confirmed** Speaker to be confirmed
12:00	**Title to be confirmed** Speaker to be confirmed
12:30	**Title to be confirmed** Speaker to be confirmed

13:00	**Lunch** **Lunchtime symposium** Speaker to be confirmed
14:00	**Plenary session: 'Immuno-radiotherapy'** Professor Sandra Demaria, Professor of Radiation Oncology, Pathology and Laboratory Medicine, Weil Cornell Medicine
15:00	**Break**

Session 3: Safety and regulation

15:30	**UKHSA – National initiative in patient safety in radiotherapy** Speaker to be confirmed
16:00	**NHSEI – National initiatives in patient safety in healthcare** Speaker to be confirmed
16:30	**CQC – IR(ME)R Compliance – what good looks like** Speaker to be confirmed
17:00	**Plenary session: Role extension and skill mix** Speaker to be confirmed
17:30	**Close of event**

BIR
The British Institute of Radiology
1897 125 Years 2022

APPROVED BY THE BIR

With sincere thanks to our platinum sponsors

BAYER

PHILIPS

GE

SIEMENS Healthineers

Advanced Accelerator Applications
A Novartis Company

@BIR_News

/britishinstituteofradiology

The British Institute of Radiology

48–50 St John Street, London, EC1M 4DG
www.bir.org.uk

Registered charity number: 215869